Omnicell, Inc. (OMCL) – What Are Investment Firms Thinking About This Stock?

Shares of Omnicell, Inc. (NASDAQ:OMCL) have earned an average rating of “Moderate Buy” from the nine analysts that are currently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $57.86.

Several equities analysts have recently commented on OMCL shares. KeyCorp restated an “overweight” rating on shares of Omnicell in a research report on Monday, August 24th. Weiss Ratings raised shares of Omnicell from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, August 18th. Zacks Research upgraded shares of Omnicell from a “strong sell” rating to a “hold” rating in a research report on Monday, September 7th. Wells Fargo & Company reduced their target price on shares of Omnicell from $55.00 to $50.00 and set an “overweight” rating for the company in a research note on Friday, July 31st. Finally, Piper Sandler reissued an “overweight” rating and set a $45.00 target price (down from $55.00) on shares of Omnicell in a research note on Monday, August 3rd.

Omnicell Trading Down 2.9%

NASDAQ:OMCL opened at $35.39 on Friday. Omnicell has a 12-month low of $29.06 and a 12-month high of $55.00. The firm has a market capitalization of $1.61 billion, a P/E ratio of 23.67, a P/E/G ratio of 0.91 and a beta of 0.98. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.64 and a quick ratio of 1.43. The business has a 50 day simple moving average of $34.59 and a 200 day simple moving average of $38.48.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings data on Thursday, July 30th. The company reported $0.94 EPS for the quarter, topping analysts’ consensus estimates of $0.47 by $0.47. The firm had revenue of $312.21 million during the quarter, compared to the consensus estimate of $310.21 million. Omnicell had a return on equity of 5.66% and a net margin of 3.13%. The firm’s revenue was up 7.4% on a year-over-year basis. During the same period in the prior year, the business earned $0.45 EPS. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. Equities research analysts predict that Omnicell will post 1.41 EPS for the current year.

Institutional Investors Weigh In On Omnicell

A number of hedge funds have recently made changes to their positions in OMCL. Central Pacific Bank Trust Division acquired a new position in shares of Omnicell during the third quarter worth approximately $107,000. Cim Investment Management Inc. bought a new position in Omnicell in the 2nd quarter worth approximately $213,000. Squarepoint Ops LLC grew its holdings in Omnicell by 80.8% in the 2nd quarter. Squarepoint Ops LLC now owns 120,419 shares of the company’s stock worth $5,000,000 after buying an additional 53,807 shares in the last quarter. Nykredit A S acquired a new stake in Omnicell in the 2nd quarter valued at approximately $26,000. Finally, Corient Private Wealth LP increased its position in Omnicell by 46.7% in the 2nd quarter. Corient Private Wealth LP now owns 62,809 shares of the company’s stock valued at $2,608,000 after acquiring an additional 20,000 shares during the period. Institutional investors own 97.70% of the company’s stock.

About Omnicell

Omnicell, Inc provides medication-management technology and related services for health care providers. Its solutions are designed to help hospitals, health systems, retail pharmacies and other care settings manage medication inventory, improve workflow efficiency and support medication adherence.

The company’s offerings include automated medication dispensing systems, central pharmacy automation, medication packaging and adherence solutions, pharmacy inventory management tools, and software for medication-use analytics and workflow management.